Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 800

1.

Impaired differentiation and cytotoxicity of natural killer cells in systemic lupus erythematosus.

Park YW, Kee SJ, Cho YN, Lee EH, Lee HY, Kim EM, Shin MH, Park JJ, Kim TJ, Lee SS, Yoo DH, Kang HS.

Arthritis Rheum. 2009 Jun;60(6):1753-63. doi: 10.1002/art.24556.

2.

Natural killer cell activity in families of patients with systemic lupus erythematosus: demonstration of a killing defect in patients.

Green MR, Kennell AS, Larche MJ, Seifert MH, Isenberg DA, Salaman MR.

Clin Exp Immunol. 2005 Jul;141(1):165-73.

3.

Impaired release of a soluble natural killer cytotoxic factor in systemic lupus erythematosus.

Sibbitt WL Jr, Mathews PM, Bankhurst AD.

Arthritis Rheum. 1984 Oct;27(10):1095-100.

PMID:
6487394
4.

Defective natural killer (NK) and killer (K) cell function in systemic lupus erythematosus.

Ewan PW, Barrett HM, Pusey CD.

J Clin Lab Immunol. 1983 Feb;10(2):71-6.

PMID:
6842577
5.

Increase in activated CD8+ T lymphocytes expressing perforin and granzyme B correlates with disease activity in patients with systemic lupus erythematosus.

Blanco P, Pitard V, Viallard JF, Taupin JL, Pellegrin JL, Moreau JF.

Arthritis Rheum. 2005 Jan;52(1):201-11.

6.

A killing defect of natural killer cells as an underlying immunologic abnormality in childhood systemic lupus erythematosus.

Yabuhara A, Yang FC, Nakazawa T, Iwasaki Y, Mori T, Koike K, Kawai H, Komiyama A.

J Rheumatol. 1996 Jan;23(1):171-7.

PMID:
8838528
7.

Numerical and functional deficiencies of natural killer T cells in systemic lupus erythematosus: their deficiency related to disease activity.

Cho YN, Kee SJ, Lee SJ, Seo SR, Kim TJ, Lee SS, Kim MS, Lee WW, Yoo DH, Kim N, Park YW.

Rheumatology (Oxford). 2011 Jun;50(6):1054-63. doi: 10.1093/rheumatology/keq457. Epub 2011 Jan 27.

PMID:
21278064
8.

Phenotype and function of natural killer cells in systemic lupus erythematosus: excess interferon-γ production in patients with active disease.

Hervier B, Beziat V, Haroche J, Mathian A, Lebon P, Ghillani-Dalbin P, Musset L, Debré P, Amoura Z, Vieillard V.

Arthritis Rheum. 2011 Jun;63(6):1698-706. doi: 10.1002/art.30313.

9.

Dysfunction of T cell receptor AV24AJ18+, BV11+ double-negative regulatory natural killer T cells in autoimmune diseases.

Kojo S, Adachi Y, Keino H, Taniguchi M, Sumida T.

Arthritis Rheum. 2001 May;44(5):1127-38.

10.
11.

[Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells].

Shi YX, Zhang XS, Xia JC, Li YQ, Xu RH, Han WJ, Zhang JH, Guan ZZ, Jiang WQ.

Ai Zheng. 2007 Aug;26(8):837-42. Chinese.

PMID:
17697543
12.

Interferon-alpha regulation of lymphocyte function in systemic lupus erythematosus.

Sibbitt WL Jr, Froelich CJ, Bankhurst AD.

Clin Immunol Immunopathol. 1984 Jul;32(1):70-80.

PMID:
6733982
14.

The quantitative analysis of peripheral blood FOXP3-expressing T cells in systemic lupus erythematosus and rheumatoid arthritis patients.

Lin SC, Chen KH, Lin CH, Kuo CC, Ling QD, Chan CH.

Eur J Clin Invest. 2007 Dec;37(12):987-96.

PMID:
18036033
17.

Abnormal natural killer cell activity in systemic lupus erythematosus: an intrinsic defect in the lytic event.

Katz P, Zaytoun AM, Lee JH Jr, Panush RS, Longley S.

J Immunol. 1982 Nov;129(5):1966-71.

PMID:
7119439
18.

Natural killer T cells in families of patients with systemic lupus erythematosus: their possible role in regulation of IGG production.

Green MR, Kennell AS, Larche MJ, Seifert MH, Isenberg DA, Salaman MR.

Arthritis Rheum. 2007 Jan;56(1):303-10.

19.

Defective phosphorylation of interleukin-18 receptor beta causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis.

de Jager W, Vastert SJ, Beekman JM, Wulffraat NM, Kuis W, Coffer PJ, Prakken BJ.

Arthritis Rheum. 2009 Sep;60(9):2782-93. doi: 10.1002/art.24750.

20.

Age related natural killer activity of peripheral blood lymphocytes from healthy subjects and cancer patients. A comparative in vitro study with interleukin-2.

Chakraborty A, Chakraborty NG, Chattopadhyay U.

Tumori. 1994 Jun 30;80(3):233-7. Erratum in: Tumori 1995 May-Jun;81(3):following 224.

PMID:
8053083

Supplemental Content

Support Center